SOCS3 and STAT3, major controllers of the outcome of infection with Mycobacterium tuberculosis

Seminars in Immunology

Volumn 26, Issue 6, 2014, Pages 518-532

  Rottenberg, Martin E ^a   Carow, Berit ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dendritic cell; M. tuberculosis; Macrophage; SOCS3; STAT3; T cell

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 6; NITRIC OXIDE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; SOCS3 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

APOPTOSIS; AUTOPHAGY; BONE MARROW CELL; CELL DIFFERENTIATION; CELL POPULATION; GAMMA DELTA T LYMPHOCYTE; HELPER CELL; IMMUNE RESPONSE; MEMORY T LYMPHOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHAGOCYTE; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; ANIMAL; DENDRITIC CELL; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; LUNG TUBERCULOSIS; MACROPHAGE; MICROBIOLOGY; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; MACROPHAGES; MICE; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES; TUBERCULOSIS, PULMONARY;

EID: 84919969351     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.10.004     Document Type: Review

References (260)

1. WHO Global tuberculosis report 2012, WHO, Geneva, Switzerland.
2. Hirahara K., Vahedi G., Ghoreschi K., Yang X.P., Nakayamada S., Kanno Y., et al. Helper T-cell differentiation and plasticity: insights from epigenetics. Immunology 2011, 134:235-245.
3. Ihle J.N. STATs: signal transducers and activators of transcription. Cell 1996, 84:331-334.
4. O'Shea J.J. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?. Immunity 1997, 7:1-11.
5. Dupuis S., Dargemont C., Fieschi C., Thomassin N., Rosenzweig S., Harris J., et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001, 293:300-303.
6. Casanova J.L., Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002, 20:581-620.
7. Sabri A., Grant A.V., Cosker K., El Azbaoui S., Abid A., Abderrahmani Rhorfi I., et al. Association study of genes controlling IL-12-dependent IFN-gamma immunity: STAT4 alleles increase risk of pulmonary tuberculosis in morocco. J Infect Dis 2014, 210:611-618.
8. Cooper A.M., Adams L.B., Dalton D.K., Appelberg R., Ehlers S. IFN-gamma and NO in mycobacterial disease: new jobs for old hands. Trends Microbiol 2002, 10:221-226.
9. Ehlers S., Benini J., Held H.D., Roeck C., Alber G., Uhlig S. Alphabeta T cell receptor-positive cells and interferon-gamma, but not inducible nitric oxide synthase, are critical for granuloma necrosis in a mouse model of mycobacteria-induced pulmonary immunopathology. J Exp Med 2001, 194:1847-1859.
10. Vinkemeier U. Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 2004, 167:197-201.
11. Bohmer F.D., Friedrich K. Protein tyrosine phosphatases as wardens of STAT signaling. JAKSTAT 2014, 3:e28087.
12. Shuai K., Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 2005, 5:593-605.
13. Silver J.S., Hunter C.A. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol 2010, 88:1145-1156.
14. Yoon S., Woo S.U., Kang J.H., Kim K., Kwon M.H., Park S., et al. STAT3 transcriptional factor activated by reactive oxygen species induces IL6 in starvation-induced autophagy of cancer cells. Autophagy 2010, 6:1125-1138.
15. Shen Y., Schlessinger K., Zhu X., Meffre E., Quimby F., Levy D.E., et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 2004, 24:407-419.
16. Yuan Z.L., Guan Y.J., Chatterjee D., Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307:269-273.
17. Yang J., Stark G.R. Roles of unphosphorylated STATs in signaling. Cell Res 2008, 18:443-451.
18. Qing Y., Stark G.R. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 2004, 279:41679-41685.
19. Takeda K., Noguchi K., Shi W., Tanaka T., Matsumoto M., Yoshida N., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997, 94:3801-3804.
20. Takeda K., Clausen B.E., Kaisho T., Tsujimura T., Terada N., Forster I., et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999, 10:39-49.
21. Williams L., Bradley L., Smith A., Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004, 172:567-576.
22. Kobayashi M., Kweon M.N., Kuwata H., Schreiber R.D., Kiyono H., Takeda K., et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 2003, 111:1297-1308.
23. Yoshimura A., Naka T., Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007, 7:454-465.
24. Carow B., Ye X., Gavier-Widen D., Bhuju S., Oehlmann W., Singh M., et al. Silencing suppressor of cytokine signaling-1 (SOCS1) in macrophages improves Mycobacterium tuberculosis control in an interferon-gamma (IFN-gamma)-dependent manner. J Biol Chem 2011, 286:26873-26887.
25. Masood K.I., Rottenberg M.E., Carow B., Rao N., Ashraf M., Hussain R., et al. SOCS1 gene expression is increased in severe pulmonary tuberculosis. Scand J Immunol 2012, 76:398-404.
26. Khor C.C., Vannberg F.O., Chapman S.J., Guo H., Wong S.H., Walley A.J., et al. CISH and susceptibility to infectious diseases. N Engl J Med 2010, 362:2092-2101.
27. Yang X.O., Zhang H., Kim B.S., Niu X., Peng J., Chen Y., et al. The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat Immunol 2013, 14:732-740.
28. Kershaw N.J., Murphy J.M., Liau N.P., Varghese L.N., Laktyushin A., Whitlock E.L., et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 2013, 20:469-476.
29. Babon J.J., Nicola N.A. The biology and mechanism of action of suppressor of cytokine signaling 3. Growth Factors 2012, 30:207-219.
30. Carow B., Rottenberg M.E. SOCS3, a major regulator of infection and inflammation. Front Immunol 2014, 5:58.
31. Marine J.C., McKay C., Wang D., Topham D.J., Parganas E., Nakajima H., et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 1999, 98:617-627.
32. Roberts A.W., Robb L., Rakar S., Hartley L., Cluse L., Nicola N.A., et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A 2001, 98:9324-9329.
33. Niemand C., Nimmesgern A., Haan S., Fischer P., Schaper F., Rossaint R., et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 2003, 170:3263-3272.
34. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
35. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003, 4:551-556.
36. Braun D.A., Fribourg M., Sealfon S.C. Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. J Biol Chem 2013, 288:2986-2993.
37. Lang R., Pauleau A.L., Parganas E., Takahashi Y., Mages J., Ihle J.N., et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003, 4:546-550.
38. Wan C.K., Oh J., Li P., West E.E., Wong E.A., Andraski A.B., et al. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 2013, 38:514-527.
39. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003, 4:540-545.
40. Redford P.S., Murray P.J., O'Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 2011, 4:261-270.
41. Dorhoi A., Desel C., Yeremeev V., Pradl L., Brinkmann V., Mollenkopf H.J., et al. The adaptor molecule CARD9 is essential for tuberculosis control. J Exp Med 2010, 207:777-792.
42. Geijtenbeek T.B., Van Vliet S.J., Koppel E.A., Sanchez-Hernandez M., Vandenbroucke-Grauls C.M., Appelmelk B., et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003, 197:7-17.
43. Tailleux L., Schwartz O., Herrmann J.L., Pivert E., Jackson M., Amara A., et al. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med 2003, 197:121-127.
44. Tanne A., Ma B., Boudou F., Tailleux L., Botella H., Badell E., et al. A murine DC-SIGN homologue contributes to early host defense against Mycobacterium tuberculosis. J Exp Med 2009, 206:2205-2220.
45. Fremond C.M., Togbe D., Doz E., Rose S., Vasseur V., Maillet I., et al. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J Immunol 2007, 179:1178-1189.
46. Shah J.A., Vary J.C., Chau T.T., Bang N.D., Yen N.T., Farrar J.J., et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. J Immunol 2012, 189:1737-1746.
47. Vazquez N., Greenwell-Wild T., Rekka S., Orenstein J.M., Wahl S.M. Mycobacterium avium-induced SOCS contributes to resistance to IFN-gamma-mediated mycobactericidal activity in human macrophages. J Leukoc Biol 2006, 80:1136-1144.
48. Carow B., Reuschl A.K., Gavier-Widen D., Jenkins B.J., Ernst M., Yoshimura A., et al. Critical and independent role for SOCS3 in either myeloid or T cells in resistance to Mycobacterium tuberculosis. PLoS Pathog 2013, 9:e1003442.
49. Narayana Y., Bansal K., Sinha A.Y., Kapoor N., Puzo G., Gilleron M., et al. SOCS3 expression induced by PIM2 requires PKC and PI3K signaling. Mol Immunol 2009, 46:2947-2954.
50. Narayana Y., Balaji K.N. NOTCH1 up-regulation and signaling involved in Mycobacterium bovis BCG-induced SOCS3 expression in macrophages. J Biol Chem 2008, 283:12501-12511.
51. Arsenault R.J., Li Y., Bell K., Doig K., Potter A., Griebel P.J., et al. Mycobacterium avium subsp. paratuberculosis inhibits gamma interferon-induced signaling in bovine monocytes: insights into the cellular mechanisms of Johne's disease. Infect Immun 2012, 80:3039-3048.
52. Nair S., Pandey A.D., Mukhopadhyay S. The PPE18 protein of Mycobacterium tuberculosis inhibits NF-kappaB/rel-mediated proinflammatory cytokine production by upregulating and phosphorylating suppressor of cytokine signaling 3 protein. J Immunol 2011, 186:5413-5424.
53. Imai K., Kurita-Ochiai T., Ochiai K. Mycobacterium bovis bacillus Calmette-Guerin infection promotes SOCS induction and inhibits IFN-gamma-stimulated JAK/STAT signaling in J774 macrophages. FEMS Immunol Med Microbiol 2003, 39:173-180.
54. Siddiqui K.F., Amir M., Gurram R.K., Khan N., Arora A., Rajagopal K., et al. Latency-associated protein Acr1 impairs dendritic cell maturation and functionality: a possible mechanism of immune evasion by Mycobacterium tuberculosis. J Infect Dis 2014, 209:1436-1445.
55. Palaga T., Buranaruk C., Rengpipat S., Fauq A.H., Golde T.E., Kaufmann S.H., et al. Notch signaling is activated by TLR stimulation and regulates macrophage functions. Eur J Immunol 2008, 38:174-183.
56. Monsalve E., Ruiz-Garcia A., Baladron V., Ruiz-Hidalgo M.J., Sanchez-Solana B., Rivero S., et al. Notch1 upregulates LPS-induced macrophage activation by increasing NF-kappaB activity. Eur J Immunol 2009, 39:2556-2570.
57. Radtke F., MacDonald H.R., Tacchini-Cottier F. Regulation of innate and adaptive immunity by Notch. Nat Rev Immunol 2013, 13:427-437.
58. Wang Y.C., He F., Feng F., Liu X.W., Dong G.Y., Qin H.Y., et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 2010, 70:4840-4849.
59. Masood K.I., Rottenberg M.E., Salahuddin N., Irfan M., Rao N., Carow B., et al. Expression of M. tuberculosis-induced suppressor of cytokine signaling (SOCS) 1, SOCS3, FoxP3 and secretion of IL-6 associates with differing clinical severity of tuberculosis. BMC Infect Dis 2013, 13:13.
60. Matsumura Y., Kobayashi T., Ichiyama K., Yoshida R., Hashimoto M., Takimoto T., et al. Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J Immunol 2007, 179:2170-2179.
61. Liu X., Zhang Y., Yu Y., Yang X., Cao X. SOCS3 promotes TLR4 response in macrophages by feedback inhibiting TGF-beta1/Smad3 signaling. Mol Immunol 2008, 45:1405-1413.
62. Benkhart E.M., Siedlar M., Wedel A., Werner T., Ziegler-Heitbrock H.W. Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. J Immunol 2000, 165:1612-1617.
63. Kinjyo I., Inoue H., Hamano S., Fukuyama S., Yoshimura T., Koga K., et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med 2006, 203:1021-1031.
64. Kitamura H., Kamon H., Sawa S., Park S.J., Katunuma N., Ishihara K., et al. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 2005, 23:491-502.
65. Hoentjen F., Sartor R.B., Ozaki M., Jobin C. STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. Blood 2005, 105:689-696.
66. Kang Y.J., Chen J., Otsuka M., Mols J., Ren S., Wang Y., et al. Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J Immunol 2008, 180:5075-5082.
67. Wang R., Cherukuri P., Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 2005, 280:11528-11534.
68. He G., Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011, 21:159-168.
69. Liu Y., Stewart K.N., Bishop E., Marek C.J., Kluth D.C., Rees A.J., et al. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol 2008, 180:6270-6278.
70. Spence S., Fitzsimons A., Boyd C.R., Kessler J., Fitzgerald D., Elliott J., et al. Suppressors of cytokine signaling 2 and 3 diametrically control macrophage polarization. Immunity 2013, 38:66-78.
71. Qin H., Holdbrooks A.T., Liu Y., Reynolds S.L., Yanagisawa L.L., Benveniste E.N. SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J Immunol 2012, 189:3439-3448.
72. Silver J.S., Stumhofer J.S., Passos S., Ernst M., Hunter C.A. IL-6 mediates the susceptibility of glycoprotein 130 hypermorphs to Toxoplasma gondii. J Immunol 2011, 187:350-360.
73. Whitmarsh R.J., Gray C.M., Gregg B., Christian D.A., May M.J., Murray P.J., et al. A critical role for SOCS3 in innate resistance to Toxoplasma gondii. Cell Host Microbe 2011, 10:224-236.
74. O'Garra A., Redford P.S., McNab F.W., Bloom C.I., Wilkinson R.J., Berry M.P. The immune response in tuberculosis. Annu Rev Immunol 2013, 31:475-527.
75. Allie N., Grivennikov S.I., Keeton R., Hsu N.J., Bourigault M.L., Court N., et al. Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. Sci Rep 2013, 3:1809.
76. Khader S.A., Partida-Sanchez S., Bell G., Jelley-Gibbs D.M., Swain S., Pearl J.E., et al. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 2006, 203:1805-1815.
77. Orabona C., Pallotta M.T., Volpi C., Fallarino F., Vacca C., Bianchi R., et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A 2008, 105:20828-20833.
78. O'Leary S., O'Sullivan M.P., Keane J. IL-10 blocks phagosome maturation in Mycobacterium tuberculosis-infected human macrophages. Am J Respir Cell Mol Biol 2011, 45:172-180.
79. Moore K.W., De Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
80. Hmama Z., Gabathuler R., Jefferies W.A., de Jong G., Reiner N.E. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. J Immunol 1998, 161:4882-4893.
81. Demangel C., Bertolino P., Britton W.J. Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol 2002, 32:994-1002.
82. Redford P.S., Boonstra A., Read S., Pitt J., Graham C., Stavropoulos E., et al. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol 2010, 40:2200-2210.
83. Pitt J.M., Stavropoulos E., Redford P.S., Beebe A.M., Bancroft G.J., Young D.B., et al. Blockade of IL-10 signaling during bacillus Calmette-Guerin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-gamma and IL-17 responses and increases protection to Mycobacterium tuberculosis infection. J Immunol 2012, 189:4079-4087.
84. Roque S., Nobrega C., Appelberg R., Correia-Neves M. IL-10 underlies distinct susceptibility of BALB/c and C57BL/6 mice to Mycobacterium avium infection and influences efficacy of antibiotic therapy. J Immunol 2007, 178:8028-8035.
85. Cyktor J.C., Carruthers B., Kominsky R.A., Beamer G.L., Stromberg P., Turner J. IL-10 inhibits mature fibrotic granuloma formation during Mycobacterium tuberculosis infection. J Immunol 2013, 190:2778-2790.
86. Jung Y.J., Ryan L., LaCourse R., North R.J. Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice. Immunology 2003, 109:295-299.
87. Murray P.J., Young R.A. Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect Immun 1999, 67:3087-3095.
88. Leal I.S., Smedegard B., Andersen P., Appelberg R. Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. Infect Immun 1999, 67:5747-5754.
89. Martinez A.N., Mehra S., Kaushal D. Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection. J Infect Dis 2013, 207:1253-1261.
90. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
91. Ladel C.H., Blum C., Dreher A., Reifenberg K., Kopf M., Kaufmann S.H. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997, 65:4843-4849.
92. Okada M., Kita Y., Kanamaru N., Hashimoto S., Uchiyama Y., Mihara M., et al. Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-alpha antibody in mice. Clin Dev Immunol 2011, 2011:404929.
93. Saunders B.M., Frank A.A., Orme I.M., Cooper A.M. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun 2000, 68:3322-3326.
94. Sodenkamp J., Waetzig G.H., Scheller J., Seegert D., Grotzinger J., Rose-John S., et al. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology 2012, 217:996-1004.
95. Nagabhushanam V., Solache A., Ting L.M., Escaron C.J., Zhang J.Y., Ernst J.D. Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma. J Immunol 2003, 171:4750-4757.
96. Eum S.Y., Kong J.H., Hong M.S., Lee Y.J., Kim J.H., Hwang S.H., et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010, 137:122-128.
97. Barnes P.F., Leedom J.M., Chan L.S., Wong S.F., Shah J., Vachon L.A., et al. Predictors of short-term prognosis in patients with pulmonary tuberculosis. J Infect Dis 1988, 158:366-371.
98. Eruslanov E.B., Lyadova I.V., Kondratieva T.K., Majorov K.B., Scheglov I.V., Orlova M.O., et al. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect Immun 2005, 73:1744-1753.
99. Keller C., Hoffmann R., Lang R., Brandau S., Hermann C., Ehlers S. Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. Infect Immun 2006, 74:4295-4309.
100. Nandi B., Behar S.M. Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. J Exp Med 2011, 208:2251-2262.
101. Zhang X., Majlessi L., Deriaud E., Leclerc C., Lo-Man R. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009, 31:761-771.
102. Feng C.G., Kaviratne M., Rothfuchs A.G., Cheever A., Hieny S., Young H.A., et al. NK cell-derived IFN-gamma differentially regulates innate resistance and neutrophil response in T cell-deficient hosts infected with Mycobacterium tuberculosis. J Immunol 2006, 177:7086-7093.
103. Appelberg R., Castro A.G., Gomes S., Pedrosa J., Silva M.T. Susceptibility of beige mice to Mycobacterium avium: role of neutrophils. Infect Immun 1995, 63:3381-3387.
104. Rivas-Santiago B., Hernandez-Pando R., Carranza C., Juarez E., Contreras J.L., Aguilar-Leon D., et al. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect Immun 2008, 76:935-941.
105. Martineau A.R., Newton S.M., Wilkinson K.A., Kampmann B., Hall B.M., Nawroly N., et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007, 117:1988-1994.
106. Saiga H., Nishimura J., Kuwata H., Okuyama M., Matsumoto S., Sato S., et al. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. J Immunol 2008, 181:8521-8527.
107. Johnson E.E., Srikanth C.V., Sandgren A., Harrington L., Trebicka E., Wang L., et al. Siderocalin inhibits the intracellular replication of Mycobacterium tuberculosis in macrophages. FEMS Immunol Med Microbiol 2010, 58:138-145.
108. McLemore M.L., Grewal S., Liu F., Archambault A., Poursine-Laurent J., Haug J., et al. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 2001, 14:193-204.
109. Numata A., Shimoda K., Kamezaki K., Haro T., Kakumitsu H., Shide K., et al. Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer-binding protein alpha in granulocyte colony-stimulating factor signaling pathway. J Biol Chem 2005, 280:12621-12629.
110. Panopoulos A.D., Zhang L., Snow J.W., Jones D.M., Smith A.M., El Kasmi K.C., et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood 2006, 108:3682-3690.
111. Nguyen-Jackson H., Panopoulos A.D., Zhang H., Li H.S., Watowich S.S. STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and via modulation of CXCR2 signal transduction. Blood 2010, 115:3354-3363.
112. Guglani L., Gopal R., Rangel-Moreno J., Junecko B.F., Lin Y., Berger T., et al. Lipocalin 2 regulates inflammation during pulmonary mycobacterial infections. PLoS ONE 2012, 7:e50052.
113. Ye P., Rodriguez F.H., Kanaly S., Stocking K.L., Schurr J., Schwarzenberger P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001, 194:519-527.
114. Witowski J., Pawlaczyk K., Breborowicz A., Scheuren A., Kuzlan-Pawlaczyk M., Wisniewska J., et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000, 165:5814-5821.
115. Laan M., Cui Z.H., Hoshino H., Lotvall J., Sjostrand M., Gruenert D.C., et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999, 162:2347-2352.
116. Nouailles G., Dorhoi A., Koch M., Zerrahn J., Weiner J., Fae K.C., et al. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest 2014, 124:1268-1282.
117. Blomgran R., Ernst J.D. Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during Mycobacterium tuberculosis infection. J Immunol 2011, 186:7110-7119.
118. Blomgran R., Desvignes L., Briken V., Ernst J.D. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe 2012, 11:81-90.
119. Kamezaki K., Shimoda K., Numata A., Haro T., Kakumitsu H., Yoshie M., et al. Roles of Stat3 and ERK in G-CSF signaling. Stem Cells 2005, 23:252-263.
120. Lee C.K., Raz R., Gimeno R., Gertner R., Wistinghausen B., Takeshita K., et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 2002, 17:63-72.
121. Croker B.A., Metcalf D., Robb L., Wei W., Mifsud S., DiRago L., et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 2004, 20:153-165.
122. Croker B.A., Mielke L.A., Wormald S., Metcalf D., Kiu H., Alexander W.S., et al. Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation. Exp Hematol 2008, 36:786-798.
123. Bermudez L.E., Petrofsky M., Stevens P. Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice. Immunology 1998, 94:297-303.
124. George S., Coffey M., Cinti S., Collins J., Brown M., Kazanjian P. Neutrophils from AIDS patients treated with granulocyte colony-stimulating factor demonstrate enhanced killing of Mycobacterium avium. J Infect Dis 1998, 178:1530-1533.
125. MacMicking J.D., North R.J., LaCourse R., Mudgett J.S., Shah S.K., Nathan C.F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A 1997, 94:5243-5248.
126. Chan J., Tanaka K., Carroll D., Flynn J., Bloom B.R. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 1995, 63:736-740.
127. Modolell M., Corraliza I.M., Link F., Soler G., Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol 1995, 25:1101-1104.
128. El Kasmi K.C., Qualls J.E., Pesce J.T., Smith A.M., Thompson R.W., Henao-Tamayo M., et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 2008, 9:1399-1406.
129. Qualls J.E., Neale G., Smith A.M., Koo M.S., DeFreitas A.A., Zhang H., et al. Arginine usage in mycobacteria-infected macrophages depends on autocrine-paracrine cytokine signaling. Sci Signal 2010, 3:ra62.
130. Schreiber T., Ehlers S., Heitmann L., Rausch A., Mages J., Murray P.J., et al. Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J Immunol 2009, 183:1301-1312.
131. Mathur R.K., Awasthi A., Wadhone P., Ramanamurthy B., Saha B. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med 2004, 10:540-544.
132. Jacobs M., Fick L., Allie N., Brown N., Ryffel B. Enhanced immune response in Mycobacterium bovis bacille calmette guerin (BCG)-infected IL-10-deficient mice. Clin Chem Lab Med 2002, 40:893-902.
133. Nicholson S., Bonecini-Almeida Mda G., Lapa e Silva J.R., Nathan C., Xie Q.W., Mumford R., et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996, 183:2293-2302.
134. Wang C.H., Liu C.Y., Lin H.C., Yu C.T., Chung K.F., Kuo H.P. Increased exhaled nitric oxide in active pulmonary tuberculosis due to inducible NO synthase upregulation in alveolar macrophages. Eur Respir J 1998, 11:809-815.
135. Mattila J.T., Ojo O.O., Kepka-Lenhart D., Marino S., Kim J.H., Eum S.Y., et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 2013, 191:773-784.
136. Weinberg J.B., Misukonis M.A., Shami P.J., Mason S.N., Sauls D.L., Dittman W.A., et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995, 86:1184-1195.
137. Jung J.Y., Madan-Lala R., Georgieva M., Rengarajan J., Sohaskey C.D., Bange F.C., et al. The intracellular environment of human macrophages that produce nitric oxide promotes growth of mycobacteria. Infect Immun 2013, 81:3198-3209.
138. Divangahi M., Behar S.M., Remold H. Dying to live: how the death modality of the infected macrophage affects immunity to tuberculosis. Adv Exp Med Biol 2013, 783:103-120.
139. Xu G., Wang J., Gao G.F., Liu C.H. Insights into battles between Mycobacterium tuberculosis and macrophages. Protein Cell 2014, 5:728-736.
140. Sly L.M., Hingley-Wilson S.M., Reiner N.E., McMaster W.R. Survival of Mycobacterium tuberculosis in host macrophages involves resistance to apoptosis dependent upon induction of antiapoptotic Bcl-2 family member Mcl-1. J Immunol 2003, 170:430-437.
141. Schaible U.E., Winau F., Sieling P.A., Fischer K., Collins H.L., Hagens K., et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003, 9:1039-1046.
142. Gil D.P., Leon L.G., Correa L.I., Maya J.R., Paris S.C., Garcia L.F., et al. Differential induction of apoptosis and necrosis in monocytes from patients with tuberculosis and healthy control subjects. J Infect Dis 2004, 189:2120-2128.
143. Bournazou E., Bromberg J. Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT 2013, 2:e23828.
144. Castillo E.F., Dekonenko A., Arko-Mensah J., Mandell M.A., Dupont N., Jiang S., et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci U S A 2012, 109:E3168-E3176.
145. Yu X., Li C., Hong W., Pan W., Xie J. Autophagy during Mycobacterium tuberculosis infection and implications for future tuberculosis medications. Cell Signal 2013, 25:1272-1278.
146. Gutierrez M.G., Master S.S., Singh S.B., Taylor G.A., Colombo M.I., Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004, 119:753-766.
147. Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H., et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell 2012, 48:667-680.
148. Van Grol J., Subauste C., Andrade R.M., Fujinaga K., Nelson J., Subauste C.S. HIV-1 inhibits autophagy in bystander macrophage/monocytic cells through Src-Akt and STAT3. PLoS ONE 2010, 5:e11733.
149. Vahedi G., Takahashi H., Nakayamada S., Sun H.W., Sartorelli V., Kanno Y., et al. STATs shape the active enhancer landscape of T cell populations. Cell 2012, 151:981-993.
150. Vignali D.A., Kuchroo V.K. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012, 13:722-728.
151. Yamamoto K., Yamaguchi M., Miyasaka N., Miura O. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochem Biophys Res Commun 2003, 310:1188-1193.
152. Chen Z., Laurence A., Kanno Y., Pacher-Zavisin M., Zhu B.M., Tato C., et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A 2006, 103:8137-8142.
153. Brender C., Tannahill G.M., Jenkins B.J., Fletcher J., Columbus R., Saris C.J., et al. Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27. Blood 2007, 110:2528-2536.
154. Altare F., Durandy A., Lammas D., Emile J.F., Lamhamedi S., Le Deist F., et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998, 280:1432-1435.
155. Picard C., Fieschi C., Altare F., Al-Jumaah S., Al-Hajjar S., Feinberg J., et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 2002, 70:336-348.
156. Remus N., El Baghdadi J., Fieschi C., Feinberg J., Quintin T., Chentoufi M., et al. Association of IL12RB1 polymorphisms with pulmonary tuberculosis in adults in Morocco. J Infect Dis 2004, 190:580-587.
157. Altare F., Ensser A., Breiman A., Reichenbach J., Baghdadi J.E., Fischer A., et al. Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J Infect Dis 2001, 184:231-236.
158. Langrish C.L., McKenzie B.S., Wilson N.J., De Waal Malefyt R., Kastelein R.A., Cua D.J. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004, 202:96-105.
159. Cooper A.M., Roberts A.D., Rhoades E.R., Callahan J.E., Getzy D.M., Orme I.M. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995, 84:423-432.
160. Cooper A.M., Kipnis A., Turner J., Magram J., Ferrante J., Orme I.M. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol 2002, 168:1322-1327.
161. Seki Y., Inoue H., Nagata N., Hayashi K., Fukuyama S., Matsumoto K., et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med 2003, 9:1047-1054.
162. Egwuagu C.E., Yu C.R., Zhang M., Mahdi R.M., Kim S.J., Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J Immunol 2002, 168:3181-3187.
163. Cui W., Liu Y., Weinstein J.S., Craft J., Kaech S.M. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 2011, 35:792-805.
164. Horiuchi Y., Bae S.J., Katayama I. Overexpression of the suppressor of cytokine signalling 3 (SOCS3) in severe atopic dermatitis. Clin Exp Dermatol 2006, 31:100-104.
165. Ekelund E., Saaf A., Tengvall-Linder M., Melen E., Link J., Barker J., et al. Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis. Am J Hum Genet 2006, 78:1060-1065.
166. Nakaya M., Hamano S., Kawasumi M., Yoshida H., Yoshimura A., Kobayashi T. Aberrant IL-4 production by SOCS3-over-expressing T cells during infection with Leishmania major exacerbates disease manifestations. Int Immunol 2011, 23:195-202.
167. Moriwaki A., Inoue H., Nakano T., Matsunaga Y., Matsuno Y., Matsumoto T., et al. T cell treatment with small interfering RNA for suppressor of cytokine signaling 3 modulates allergic airway responses in a murine model of asthma. Am J Respir Cell Mol Biol 2011, 44:448-455.
168. Jacobsen M., Repsilber D., Kleinsteuber K., Gutschmidt A., Schommer-Leitner S., Black G., et al. Suppressor of cytokine signaling-3 is affected in T-cells from tuberculosisTB patients. Clin Microbiol Infect 2011, 17:1323-1331.
169. Mistry R., Cliff J.M., Clayton C.L., Beyers N., Mohamed Y.S., Wilson P.A., et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 2007, 195:357-365.
170. Ashenafi S., Aderaye G., Bekele A., Zewdie M., Aseffa G., Hoang A.T., et al. Progression of clinical tuberculosis is associated with a Th2 immune response signature in combination with elevated levels of SOCS3. Clin Immunol 2014, 151:84-99.
171. Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
172. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
173. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
174. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
175. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
176. de Beaucoudrey L., Puel A., Filipe-Santos O., Cobat A., Ghandil P., Chrabieh M., et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 2008, 205:1543-1550.
177. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
178. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.
179. Chen X., Zhang M., Liao M., Graner M.W., Wu C., Yang Q., et al. Reduced Th17 response in patients with tuberculosis correlates with IL-6R expression on CD4+ T Cells. Am J Respir Crit Care Med 2010, 181:734-742.
180. Bandaru A., Devalraju K.P., Paidipally P., Dhiman R., Venkatasubramanian S., Barnes P.F., et al. Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection. Eur J Immunol 2014.
181. Perreau M., Rozot V., Welles H.C., Belluti-Enders F., Vigano S., Maillard M., et al. Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease. Eur J Immunol 2013, 43:939-948.
182. Scriba T.J., Kalsdorf B., Abrahams D.A., Isaacs F., Hofmeister J., Black G., et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008, 180:1962-1970.
183. Ben-Selma W., Boukadida J. IL23R(Arg381Gln) functional polymorphism is associated with active pulmonary tuberculosis severity. Clin Vaccine Immunol 2012, 19:1188-1192.
184. Basile J.I., Geffner L.J., Romero M.M., Balboa L., Sabio Y.G.C., Ritacco V., et al. Outbreaks of Mycobacterium tuberculosis MDR strains induce high IL-17 T-cell response in patients with MDR tuberculosis that is closely associated with high antigen load. J Infect Dis 2011, 204:1054-1064.
185. Khader S.A., Guglani L., Rangel-Moreno J., Gopal R., Junecko B.A., Fountain J.J., et al. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 2011, 187:5402-5407.
186. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
187. Khader S.A., Pearl J.E., Sakamoto K., Gilmartin L., Bell G.K., Jelley-Gibbs D.M., et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005, 175:788-795.
188. Chackerian A.A., Chen S.J., Brodie S.J., Mattson J.D., McClanahan T.K., Kastelein R.A., et al. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun 2006, 74:6092-6099.
189. Freches D., Korf H., Denis O., Havaux X., Huygen K., Romano M. Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. Immunology 2013, 140:220-231.
190. Gopal R., Monin L., Slight S., Uche U., Blanchard E., Fallert Junecko B.A., et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog 2014, 10:e1004099.
191. Wozniak T.M., Saunders B.M., Ryan A.A., Britton W.J. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun 2010, 78:4187-4194.
192. Okamoto Yoshida Y., Umemura M., Yahagi A., O'Brien R.L., Ikuta K., Kishihara K., et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010, 184:4414-4422.
193. Cruz A., Fraga A.G., Fountain J.J., Rangel-Moreno J., Torrado E., Saraiva M., et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010, 207:1609-1616.
194. Cruz A., Khader S.A., Torrado E., Fraga A., Pearl J.E., Pedrosa J., et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol 2006, 177:1416-1420.
195. Desvignes L., Ernst J.D. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 2009, 31:974-985.
196. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
197. Meraviglia S., El Daker S., Dieli F., Martini F., Martino A. gammadelta T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection. Clin Dev Immunol 2011, 2011:587315.
198. Pinheiro M.B., Antonelli L.R., Sathler-Avelar R., Vitelli-Avelar D.M., Spindola-de-Miranda S., Guimaraes T.M., et al. CD4-CD8-alphabeta and gammadelta T cells display inflammatory and regulatory potentials during human tuberculosis. PLoS ONE 2012, 7:e50923.
199. D'Souza C.D., Cooper A.M., Frank A.A., Mazzaccaro R.J., Bloom B.R., Orme I.M. An anti-inflammatory role for gamma delta T lymphocytes in acquired immunity to Mycobacterium tuberculosis. J Immunol 1997, 158:1217-1221.
200. Ladel C.H., Blum C., Dreher A., Reifenberg K., Kaufmann S.H. Protective role of gamma/delta T cells and alpha/beta T cells in tuberculosis. Eur J Immunol 1995, 25:2877-2881.
201. Janis E.M., Kaufmann S.H., Schwartz R.H., Pardoll D.M. Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science 1989, 244:713-716.
202. Modlin R.L., Pirmez C., Hofman F.M., Torigian V., Uyemura K., Rea T.H., et al. Lymphocytes bearing antigen-specific gamma delta T-cell receptors accumulate in human infectious disease lesions. Nature 1989, 339:544-548.
203. Shen Y., Zhou D., Qiu L., Lai X., Simon M., Shen L., et al. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 2002, 295:2255-2258.
204. Chen C.Y., Yao S., Huang D., Wei H., Sicard H., Zeng G., et al. Phosphoantigen/IL2 expansion and differentiation of Vgamma2Vdelta2T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog 2013, 9:e1003501.
205. Kabelitz D., Bender A., Prospero T., Wesselborg S., Janssen O., Pechhold K. The primary response of human gamma/delta+T cells to Mycobacterium tuberculosis is restricted to V gamma 9-bearing cells. J Exp Med 1991, 173:1331-1338.
206. De Libero G., Casorati G., Giachino C., Carbonara C., Migone N., Matzinger P., et al. Selection by two powerful antigens may account for the presence of the major population of human peripheral gamma/delta T cells. J Exp Med 1991, 173:1311-1322.
207. Pechhold K., Wesch D., Schondelmaier S., Kabelitz D. Primary activation of V gamma 9-expressing gamma delta T cells by Mycobacterium tuberculosis. Requirement for Th1-type CD4 T cell help and inhibition by IL-10. J Immunol 1994, 152:4984-4992.
208. Prinz I., Silva-Santos B., Pennington D.J. Functional development of gammadelta T cells. Eur J Immunol 2013, 43:1988-1994.
209. Lockhart E., Green A.M., Flynn J.L. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006, 177:4662-4669.
210. Umemura M., Yahagi A., Hamada S., Begum M.D., Watanabe H., Kawakami K., et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007, 178:3786-3796.
211. Peng M.Y., Wang Z.H., Yao C.Y., Jiang L.N., Jin Q.L., Wang J., et al. Interleukin 17-producing gamma delta T cells increased in patients with active pulmonary tuberculosis. Cell Mol Immunol 2008, 5:203-208.
212. Martin B., Hirota K., Cua D.J., Stockinger B., Veldhoen M. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009, 31:321-330.
213. Pellegrini M., Calzascia T., Toe J.G., Preston S.P., Lin A.E., Elford A.R., et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144:601-613.
214. Yoshida H., Nakaya M., Miyazaki Y. Interleukin 27: a double-edged sword for offense and defense. J Leukoc Biol 2009, 86:1295-1303.
215. Villarino A.V., Stumhofer J.S., Saris C.J., Kastelein R.A., de Sauvage F.J., Hunter C.A. IL-27 limits IL-2 production during Th1 differentiation. J Immunol 2006, 176:237-247.
216. Yoshimura T., Takeda A., Hamano S., Miyazaki Y., Kinjyo I., Ishibashi T., et al. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol 2006, 177:5377-5385.
217. Stumhofer J.S., Laurence A., Wilson E.H., Huang E., Tato C.M., Johnson L.M., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006, 7:937-945.
218. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007, 8:1363-1371.
219. Hall A.O., Beiting D.P., Tato C., John B., Oldenhove G., Lombana C.G., et al. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 2012, 37:511-523.
220. de Aquino M.T., Kapil P., Hinton D.R., Phares T.W., Puntambekar S.S., Savarin C., et al. IL-27 limits central nervous system viral clearance by promoting IL-10 and enhances demyelination. J Immunol 2014, 193:285-294.
221. Schneider R., Yaneva T., Beauseigle D., El-Khoury L., Arbour N. IL-27 increases the proliferation and effector functions of human naive CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol 2011, 41:47-59.
222. Owaki T., Asakawa M., Kamiya S., Takeda K., Fukai F., Mizuguchi J., et al. IL-27 suppresses CD28-mediated [correction of medicated] IL-2 production through suppressor of cytokine signaling 3. J Immunol 2006, 176:2773-2780.
223. Robinson C.M., Nau G.J. Interleukin-12 and interleukin-27 regulate macrophage control of Mycobacterium tuberculosis. J Infect Dis 2008, 198:359-366.
224. Pearl J.E., Khader S.A., Solache A., Gilmartin L., Ghilardi N., deSauvage F., et al. IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. J Immunol 2004, 173:7490-7496.
225. Holscher C., Holscher A., Ruckerl D., Yoshimoto T., Yoshida H., Mak T., et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 2005, 174:3534-3544.
226. Batten M., Kljavin N.M., Li J., Walter M.J., de Sauvage F.J., Ghilardi N. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol 2008, 180:2752-2756.
227. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
228. Nurieva R.I., Chung Y., Hwang D., Yang X.O., Kang H.S., Ma L., et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008, 29:138-149.
229. Vogelzang A., McGuire H.M., Yu D., Sprent J., Mackay C.R., King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008, 29:127-137.
230. Batten M., Ramamoorthi N., Kljavin N.M., Ma C.S., Cox J.H., Dengler H.S., et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J Exp Med 2010, 207:2895-2906.
231. Zotos D., Coquet J.M., Zhang Y., Light A., D'Costa K., Kallies A., et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med 2010, 207:365-378.
232. Suto A., Kashiwakuma D., Kagami S., Hirose K., Watanabe N., Yokote K., et al. Development and characterization of IL-21-producing CD4+ T cells. J Exp Med 2008, 205:1369-1379.
233. Ma C.S., Avery D.T., Chan A., Batten M., Bustamante J., Boisson-Dupuis S., et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood 2012, 119:3997-4008.
234. Slight S.R., Rangel-Moreno J., Gopal R., Lin Y., Fallert Junecko B.A., Mehra S., et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. J Clin Invest 2013, 123:712-726.
235. Belkaid Y., Piccirillo C.A., Mendez S., Shevach E.M., Sacks D.L. CD4 + CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002, 420:502-507.
236. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
237. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
238. Yao Z., Kanno Y., Kerenyi M., Stephens G., Durant L., Watford W.T., et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007, 109:4368-4375.
239. Nakayama T., Yamashita M. The TCR-mediated signaling pathways that control the direction of helper T cell differentiation. Semin Immunol 2010, 22:303-309.
240. Laurence A., Amarnath S., Mariotti J., Kim Y.C., Foley J., Eckhaus M., et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 2012, 37:209-222.
241. Chen X., Das R., Komorowski R., Beres A., Hessner M.J., Mihara M., et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009, 114:891-900.
242. Burl S., Hill P.C., Jeffries D.J., Holland M.J., Fox A., Lugos M.D., et al. FOXP3 gene expression in a tuberculosis case contact study. Clin Exp Immunol 2007, 149:117-122.
243. Green A.M., Mattila J.T., Bigbee C.L., Bongers K.S., Lin P.L., Flynn J.L. CD4(+) regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection. J Infect Dis 2010, 202:533-541.
244. Shafiani S., Tucker-Heard G., Kariyone A., Takatsu K., Urdahl K.B. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 2010, 207:1409-1420.
245. Guyot-Revol V., Innes J.A., Hackforth S., Hinks T., Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006, 173:803-810.
246. Chen X., Zhou B., Li M., Deng Q., Wu X., Le X., et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol 2007, 123:50-59.
247. Sharma P.K., Saha P.K., Singh A., Sharma S.K., Ghosh B., Mitra D.K. FoxP3+ regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. Am J Respir Crit Care Med 2009, 179:1061-1070.
248. Siegel A.M., Heimall J., Freeman A.F., Hsu A.P., Brittain E., Brenchley J.M., et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 2011, 35:806-818.
249. Michel M.L., Pang D.J., Haque S.F., Potocnik A.J., Pennington D.J., Hayday A.C. Interleukin 7 (IL-7) selectively promotes mouse and human IL-17-producing gammadelta cells. Proc Natl Acad Sci U S A 2012, 109:17549-17554.
250. O'Kane C.M., Elkington P.T., Friedland J.S. Monocyte-dependent oncostatin M and TNF-alpha synergize to stimulate unopposed matrix metalloproteinase-1/3 secretion from human lung fibroblasts in tuberculosis. Eur J Immunol 2008, 38:1321-1330.
251. O'Kane C.M., Elkington P.T., Jones M.D., Caviedes L., Tovar M., Gilman R.H., et al. STAT3, p38 MAPK, and NF-kappaB drive unopposed monocyte-dependent fibroblast MMP-1 secretion in tuberculosis. Am J Respir Cell Mol Biol 2010, 43:465-474.
252. Ottmani S.E., Murray M.B., Jeon C.Y., Baker M.A., Kapur A., Lonnroth K., et al. Consultation meeting on tuberculosis and diabetes mellitus: meeting summary and recommendations. Int J Tuberc Lung Dis 2010, 14:1513-1517.
253. Emanuelli B., Peraldi P., Filloux C., Chavey C., Freidinger K., Hilton D.J., et al. SOCS-3 inhibits Insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001, 276:47944-47949.
254. Wang X., Crowe P.J., Goldstein D., Yang J.L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol 2012, 41:1181-1191.
255. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
256. Alvarez J.V., Greulich H., Sellers W.R., Meyerson M., Frank D.A. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006, 66:3162-3168.
257. Sendide K., Deghmane A.E., Pechkovsky D., Av-Gay Y., Talal A., Hmama Z. Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of cathepsin S. J Immunol 2005, 175:5324-5332.
258. Happel K.I., Lockhart E.A., Mason C.M., Porretta E., Keoshkerian E., Odden A.R., et al. Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect Immun 2005, 73:5782-5788.
259. Kozakiewicz L., Chen Y., Xu J., Wang Y., Dunussi-Joannopoulos K., Ou Q., et al. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog 2013, 9:e1003472.
260. Peng R., Yue J., Han M., Zhao Y., Liu L., Liang L. The IL-17F sequence variant is associated with susceptibility to tuberculosis. Gene 2013, 515:229-232.